Navigation Links
OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
Date:2/11/2010

HONG KONG, Feb. 11 /PRNewswire/ -- OrbusNeich today announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China.

A multicenter, randomized, controlled study, the trial will enroll 180 patients split evenly between the control and test arms at 11 sites countrywide. The primary study objective is to demonstrate the safety and effectiveness of the Genous Bio-engineered R stent compared to the Medtronic Endeavor Sprint stent.  

The study population will consist of patients ages 18 to 75 with symptoms of angina or myocardial ischemia. The primary endpoints are difference in Major Adverse Cardiac Event (MACE) rates between the two groups at 12 months following implant and 270 day angiographic Late Loss (LL). Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, in-stent thrombosis, MACE rates at 30, 60, 90, 180 and 270 days, as well as clinically driven Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR) and Target Lesion Failure (TLF) rates at 30, 60, 90, 180, 270 and 360 days.  

The first patient was enrolled in the study at Beijing Chaoyang Hospital on December 8, 2009.

"We believe that the Genous Bio-engineered R stent will provide an excellent treatment option to patients who present challenging cases with standard drug eluting stents," said Prof. Lu Shuzheng from Anzhen Hospital, principal investigator of the trial.

Al Novak, OrbusNeich's chairman and CEO, added, "We are excited to take the Genous Bio-engineered R stent into this pivotal trial in China. We expect that clinical data from this study will show positive benefits for patients, including those who
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
5. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Saint-Gobain has acquired ZenPure, a ... products, mainly for the life sciences sector. ... a state-of-the-art plant in Hangzhou, China ... globe and will bolster the range of fluid systems ... is fully in line with the Group,s strategy of ...
(Date:5/6/2015)... KENNEBUNK, Maine , May 6, 2015  Membership ... 2014, according to a Healthcare Business Strategy report ... plans, also known as Medigap or Med Supp ... December 31, 2014, a 5.2% increase from 2013. ... plans increased by 551,135 covered lives.  Though UnitedHealth ...
(Date:5/6/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7qn2gf/global_insulin ... "Global Insulin Patch Market Opportunity Analysis" report ... like ultrasound and iontophoresis are being used for ... the type of technique, their prices may vary ... patients. In long-term, it would be considered as ...
Breaking Medicine Technology:Saint-Gobain Acquires ZenPure, a Specialist in Filtration Products 2Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2Global Insulin Patch Market Opportunity Analysis 2015 2
... SPARTANBURG, S.C., Dec. 21, 2011 The jury verdict ... Ortho-McNeil-Janssen Pharmaceuticals and Johnson & Johnson, Inc. has been ... groundbreaking $327 million in civil penalties against the manufacturers ... announced the rulings on December 20 through two written ...
... 21, 2011   Uptake Medical ® today announced that ... its InterVapor ™ System for endoscopic lung volume ... the first non-surgical, endoscopic lung volume reduction system for ... natural healing processes without leaving implants or foreign materials ...
Cached Medicine Technology:Record Breaking $327 Million Verdict Upheld in Janssen Case and Request for New Trial Denied 2Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema 2Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema 3
(Date:5/6/2015)... Springs, Texas (PRWEB) May 06, 2015 ... stages of the HIMSS EMR Adoption Model, the ... paper, improve patient engagement and automate processes. The ... transitioned from paper-driven to electronic workflows, patient registration ... hard copies of consents. With HIMSS Stage 7 ...
(Date:5/6/2015)... 06, 2015 A quality built chicken coop condo ... yet practical way to raise chickens on a pasture. By ... Condo, it will have a chicken tractor that stands up to ... many years, as it is able to flex to uneven ground ... of the land are fertilized, and it will help provide the ...
(Date:5/6/2015)... 2015 Experienced Vancouver air conditioning installation ... that they will now conduct their cooling services, including ... addition to commercial and residential units. Strata complex air ... lot of technical knowledge as well as a professionally ... we will take away any old air conditioning unit ...
(Date:5/6/2015)... Chesapeake, Va. (PRWEB) May 06, 2015 ... hospital in the state of Virginia to acquire ... Vinci® surgical robot. The system upgrade includes enhanced ... many minimally invasive procedures across a wide spectrum ... surgical options, reduced pain and quicker recovery times. ...
(Date:5/6/2015)... Prime Pacific Health Innovations, the ... announce a new series of universal, one-time-use speculum ... footprint while improving treatment efficacy and saving therapists ... the world’s first waste hose designed specifically for ... claims the company’s president, Mr. Delmar Vogel. , ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:Pro Ace Care Now Does Air Conditioning Installation for Strata Complexes 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3
... First and Only Site Allows Patients to See How Drugs Actually Work ... ... PRINCETON, N.J., April 30 Today, iGuard.org, a free,patient-driven online healthcare community, ... a new level. With,almost half of all Americans taking prescription drugs, and ...
... Ind., April 30 Hillenbrand, Inc.,(NYSE: HI ) ... first dividend as a publicly traded company of $0.1825 ... payable June 30, 2008 to,shareholders of record at the ... decision by our board to approve this inaugural dividend ...
... National Pet Week, May,4-10, celebrates the relationships ... opportunity to emphasize the caretaking actions we can ... care as recommended by,your veterinarian; giving them plenty ... for your pets safe and pleasant., "Being ...
... Houston, Tex. April 30, 2008 - Despite the ... in critically ill heart failure patients, implantation of these ... for high-volume blood transfusions during and immediately after surgery. ... suggesting that the incidence of these complications may be ...
... They Don,t Fully Understand the Details ... of Their Health Insurance Plan, WESTLAKE ... insurers across the U.S., yet,contacting plan members regularly and increasing their ... ratings,more renewal business and additional sales of services to members,according to ...
... the cross hairs of radiation or chemotherapy may be ... jammed, say University of Florida scientists writing in a ... fly cells discovered that slight changes in the protein ... aptly named for their roles in triggering cell death ...
Cached Medicine News:Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 2Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 3Health News:Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 4Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 5Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 6Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 7Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 8Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 9Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 10Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 11Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 12Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 13Health News:'Destruct' triggers may be jammed in tumor cells, UF geneticists say 2
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
... dedicated high performance bio imaging system for ... of imaging chemiluminescent samples. It provides superbly ... use, thanks to new, unique image analysis ... the standard Genegnome, the Genegnome HR has ...
Medicine Products: